Table 2.

Genome‐wide off‐target evaluation via RNA‐seq and subsequent RT‐qPCR confirmation.

Gene name	Gene description	Expression level (C6G25S/Con)	Inhibition %	Knockdown efficacy% (RT‐qPCR)
CXCL5	C‐X‐C motif chemokine ligand 5	0.304	70	91
PRMT6	protein arginine methyltransferase 6	0.307	69	56
REEP3	receptor accessory protein 3	0.358	64	66
SGPP1	sphingosine‐1‐phosphate phosphatase 1	0.38	62	72
PI4K2B	phosphatidylinositol 4‐kinase type 2 beta	0.381	62	67
FEM1B	fem‐1 homolog B	0.387	61	55
TRIQK	triple QxxK/R motif containing	0.407	59	54
PA2G4	proliferation‐associated 2G4	0.419	58	57
SEC23A	SEC23 homolog A, COPII coat complex component	0.427	57	59
CLNS1A	chloride nucleotide‐sensitive channel 1A	0.441	56	65
ERO1A	endoplasmic reticulum oxidoreductase 1 alpha	0.443	56	nd
SDC2	syndecan 2	0.45	55	nd
BLMH	bleomycin hydrolase	0.455	55	nd
STYX	serine/threonine/tyrosine‐interacting protein	0.456	54	nd
GALNT7	polypeptide N‐acetylgalactosaminyltransferase 7	0.481	52	nd
BET1	Bet1 golgi vesicular membrane‐trafficking protein	0.483	52	nd
SDE2	SDE2 telomere maintenance homolog	0.486	51	nd
ZNF460	zinc finger protein 460	0.493	51	nd
CLIC4	chloride intracellular channel 4	0.494	51	nd
MAPRE2	microtubule‐associated protein RP/EB family member 2	0.499	50	nd
RAB12	RAB12, member RAS oncogene family	0.5	50	nd

Downregulated genes with fold change ≥ 2 in C6G25S‐treated Beas‐2B cells (10 nM C6G25S) compared with no siRNA control are listed and presented with expression level and inhibition % based on the expression level. The mRNA level was confirmed by RT‐qPCR and normalized to the GAPDH reference gene. ND, not determined.